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Abstract
Background: Targeting of protein antigens to dendritic cells (DC) via the DEC205 receptor enhances
presentation of antigen-derived peptides on MHC-I and MHC-II molecules and, in the presence of
costimulatory signals, antigen-specific immune responses. The immunogenicity and efficacy of DNA
vaccination can also be enhanced by fusing the encoded antigen to single chain antibodies directed against
DEC205. To further improve this strategy, we evaluated different toll-like receptor ligands (TLR) and
CD40 ligands (CD40L) as adjuvants for DNA vaccines encoding a DEC205-single-chain antibody fused to
the ovalbumin model antigen or HIV-1 Gag and assessed the priming efficacy of DNA in a DNA prime
adenoviral vector boost immunization regimen.
Results: Mice were primed with the adjuvanted DEC-205 targeted DNA vaccines and boosted with
adenoviral vectors encoding the same antigens. CD8+ T cell responses were determined after the
adenoviral booster immunization, to determine how well the different DNA immunization regimens prime
for the adenoviral boost. In the absence of adjuvants, targeting of DNA-encoded ovalbumin to DCs
suppressed CD8+ T-cell responses after the adenoviral booster immunization. CD8+ T-cell responses to
the DEC205 targeted DNA vaccines increased only slightly by adding either the TLR-9 ligand CpG, the
TLR-3 ligand Poly I:C, or CD40 ligand expression plasmids. However, the combination of both TLR-ligands
led to a strong enhancement of CD8+ T-cell responses compared to a non-targeted DNA vaccine. This
finding was confirmed using HIV Gag as antigen.
Conclusion: Although DNA prime adenoviral vector boost immunizations belong to the strongest
inducers of cytotoxic T cell responses in different animal models and humans, the CD8+ T cell responses
can be further improved by targeting the DNA encoded antigen to DEC205 in the presence of synergistic
TLR ligands CpG and Poly I:C.
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Background
Depending on their state of maturation or activation den-
dritic cells (DC) can prime antigen-specific T cells with
substantially different functional activities. While DC can
mediate peripheral T cell tolerance in the steady-state,
activation and maturation turns them into potent induc-
ers of CD4+ and CD8+ T cell immunity (reviewed in [1]).
Thus, targeting antigens to DCs is a promising strategy to
improve prevention and treatment of autoimmunity and
to raise the efficacy of vaccines against tumors and infec-
tious diseases. For targeting of DC in vivo, most of the
studies use recombinant protein antigens coupled or
fused to an antibody specific for a DC surface marker. In
addition to targeting the DCs their differentiation and
activation status needs to be controlled in order to obtain
the desired T cell response. A striking example of how DC
activation and differentiation signals can modulate T cell
responses has been obtained in experiments using an anti-
body to the DEC205 receptor (α-DEC) to target proteins
coupled to the antibody to DCs [2]. Targeting of antigens
to dendritic cells via the DEC205 receptor enhances pres-
entation of antigen-derived peptides on MHC-I and
MHC-II molecules [2,3]. Efficient loading of MHC-II mol-
ecules with DEC205-targeted antigenic peptides might
occur during the recycling of the DEC205 receptor with its
ligands through late, MHC-II-rich endosomal compart-
ments [4]. MHC-I-restricted presentation of exogenous
DEC-205-targeted antigens by dendritic cells in vivo was
shown to be dependent on the transporter of antigenic
peptides [3]. In the absence of costimulatory signals
DEC205-targeted antibody fused to antigens induced ini-
tial T cell proliferation followed by peripheral deletion
and unresponsiveness of CD4+ and CD8+ T cells [2,3].
Induction of regulatory T cells [2,3,5,6] and a novel form
of peripheral tolerance [7] could also be observed after
immunization with different DEC-205-targeted antigens
in the absence of co-stimulation. Although the precise
mechanisms leading to these different forms of peripheral
tolerance remain to be defined, simultaneous co-stimula-
tion via anti-CD40 antibodies and/or toll-like receptor
(TLR) ligands induces antigen-specific CD4+ and CD8+ T
cell immunity rather than tolerance [8-10].
Since gene-based vaccines are usually more potent induc-
ers of cytotoxic T-cell responses than protein vaccines, we
previously investigated whether the immunogenicity of
DNA vaccines could be enhanced by targeting the
encoded protein to DEC205 expressing dendritic cells
[11]. In addition to the differences in immune responses
induced by DNA and protein vaccines, a practical advan-
tage of DNA vaccines encoding DC-targeted antigens is
that the DNA vaccine can be produced in large scale under
standardized conditions more or less independent of the
vaccine antigen, while production and purification of
recombinant protein vaccines needs to be adjusted for
each antigen. Immunizing mice by in vivo electroporation
with DNA vaccines encoding HIV Gag fused to single-
chain antibodies to DEC205 allowed to reduce the DNA
dose approximately 100-fold without impairment of T
cell immunity and protection from viral challenge even in
the absence of exogenous co-stimulation. Although this
might allow overcoming the requirement for large doses,
a key obstacle to the application of DNA vaccines in
humans, the DC-targeted DNA vaccines did not enhance
immune responses above the levels obtained by DNA
immunization with high doses of non-targeted DNA vac-
cines.
Since the immunogenicity of viral vector vaccines can be
improved by priming with DNA vaccines in various ani-
mal models including non-human primates (reviewed in
[12]) and humans [13-15], we now explored whether tar-
geting of DNA vaccine encoded antigens to DCs can
increase the priming efficacy of the DNA vaccines in DNA
prime viral vector boost regimens. In addition, the
requirement for additional stimuli during priming with
the DEC205-targeted DNA vaccines was analysed.
Methods
DNA and viral vector vaccines
Plasmids and adenoviral vectors expressing Ovalbumin or
HIV GagPol, which were used in this study, are listed in
Table 1. To target the plasmid encoded antigens to den-
dritic cells, they were fused to a single chain antibody
directed against the DC surface receptor DEC205 as
described previously. Plasmids encoding the antigens
fused to a nonreactive antibody with different variable
light- and heavy-chain V regions were used as controls
[11]. Constructs were confirmed by sequence analysis. For
in vivo experiments all plasmids were prepared using the
Table 1: Plasmids and adenoviral vectors
Construct Backbone Single chain antibody Antigen Ref.
DEC-OVA pcDNA.3.1 Anti-DEC205 Ovalbumin 11
Con-OVA pcDNA.3.1 Non-reactive Ovalbumin 11
DEC-p41 pcDNA.3.1 Anti-DEC205 HIV Gag-p41 11
Con-p41 pcDNA.3.1 Non-reactive HIV Gag-p41 11
Ad-OVA AdV --- Ovalbumin 16
Ad-Hgpsyn AdV --- HIV GagPol 17
Ad-GFP AdV --- Green Fluorescence Protein 18BMC Immunology 2009, 10:43 http://www.biomedcentral.com/1471-2172/10/43
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Qiagen Endo-Free plasmid kit (Hilden, Germany). The
Limulus Amebocyte Lysate QCL-1000®  kit (Cambrex,
Charles City, IA, USA) was used to confirm that the Endo-
toxin concentration were below 0,1 EU (Endotoxin Units)
per dose. Construction of the Ad-Ova, Ad-Hgpsyn, and Ad-
GFP vector has been previously described [16-18]. Vector
particles grown on 293A cells were purified by the
AdenoPack100 kit (Vivascience, Goettingen, Germany).
Particle concentrations were determined by measuring the
optical density and the 50% tissue culture infectious dose
(TCID50) was determined on 293A cells. Mock immuniza-
tions were performed with an empty vector plasmid
(pcDNA3.1+)
To study the adjuvant properties of multimerized CD40L
we used plasmids encoding different multimerized forms
of CD40L, which have been previously described [19].
CpG-C (Coley Pharmaceuticals, Wellesley, MA, USA) and
Poly I:C (Invivogen, Toulouse, France) were used at a dose
of 50 μg per injection.
Immunization
6–8 week old female BALB/c and C57/Bl6 were obtained
from Charles River (Sulzfeld, Germany) and Janvier (Le
Genest-ST-Isle, France), respectively and housed in singly-
ventilated cages in accordance with the national law and
institutional guidelines. DNA vaccines (2–50 μg) were
delivered subcutaneously into both anterior foot pads in
a total volume of 100 μl PBS. Plasmids encoding mul-
timerized forms of CD40L (50 μg) or the TLR Ligands
CpG-C (Coley Pharmaceuticals, Wellesley, MA, USA) and
Poly I:C (Invivogen, Toulouse, France) were mixed with
the antigen expressing plasmids prior to injection in a
final volume of 100 μl. CpG-C and Poly I:C were used at
a dose of 50 μg per injection. Five weeks later mice were
boosted with 5 × 108 adenoviral vector particles in 100 μl
PBS by the same route.
Tetramer staining
Ova-specific CD8+ T-cell responses were measured seven
days after the booster immunization by tetramer staining.
After red blood cell lysis, 1 × 106 splenocytes were plated
in 96-well round-bottom plates (Nunc, Wiesbaden, Ger-
many) for each staining.
Cells were washed once in PBS/BSA/Azide and then incu-
bated with 2 μl of SIINFEKL/H-2Kb-APC tetramers (San-
quin, Amsterdam, NL) in total volume of 100 μl PBS/BSA/
Azide for 40 min at room temperature. Afterwards surface
staining with α-CD8-FITC was performed for 20 min at
room temperature and cells incubated with 7-amino-
actinomycin D (7-AAD) for 5 min to exclude dead cells
from subsequent FACS analyses. Analysis was performed
using a FACScalibur™ (BD Biosciences, Heidelberg, Ger-
many).
Intracellular cytokine staining (ICS)
To analyse antigen-specific T-cell responses via ICS splen-
ocytes were stimulated for 6 h in the presence of 2 μM
Monensin, which inhibits the cytokine secretion, and 1 μl
α-CD107a-FITC, which is a marker for lymphocyte
degranulation [20]. Cells were either stimulated by SIIN-
FEKL (Ovalbumin257–264, 2 μg/ml) or AMQMLKETI (HIV
Gag197–205, 2 μg/ml) and compared to non-stimulated
cultures. After stimulation, surface staining was carried
out with αCD8-PerCP or αCD4-FITC (BD Bioscience).
Cells were fixed in 2% paraformaldehyde, followed by
permeabilisation with 0,5% Saponin in PBS/BSA/Azide
buffer. Cytokines were detected with αIFN-γ-PE and αIL-
2-AlexaFluor647 (BD Bioscience).
In vivo cytotoxicity assay
To analyse in vivo CTL responses, spleen cells were isolated
from syngenic donor mice. Splenocytes were divided into
two groups and labelled either with 6 μM (CFSEhigh) or
0.3 μM (CFSElow). After several washing steps the CFSEhigh
fraction was loaded for 30 min at 37°C with 10 μg/ml
SIINFEKL (Ovalbumin257–264) or AMQMLKETI (HIV
Gag197–205,) peptides. Peptide-loaded cells (CFSEhigh)
were mixed in a one to one ratio with unloaded cells
(CFSElow) and appropriately 1.5 × 107 cells in a total vol-
ume of 300 μl PBS were injected into the tail vein of
immunized or control mice. One day post-injection mice
were sacrificed. Spleen cells were isolated and the ratio of
CFSEhigh to CFSElow labelled spleen cells were determined
by flow cytometry.
Statistical analysis
Statistical analysis was performed using the GraphPad
Prism 4.0 software (Graph, software Inc., San Diego, CA,
USA). In case the one-way ANOVA test revealed a statisti-
cal significant difference, the Bonferroni Multiple Com-
parison test was used to determine the level statistical
significance between two groups.
Results
In several experimental systems, DNA prime viral vector
boost immunization regimens are the most potent induc-
ers of CD8+ T-cell responses (reviewed in [21]). Although
the DNA prime itself only induces weak immune
responses, CD8+ T-cell responses are substantially higher
after the viral boost compared to DNA prime DNA boost
immunization or viral vector immunizations in the
absence of DNA priming. We therefore modified the DNA
priming conditions and analysed the effect of DNA prim-
ing on CD8+ T-cell responses after a constant viral vector
boost to directly assess the potency of the combined DNA
prime viral vector boost regimen.
To determine the effect of targeting the antigen expressed
by the DNA vaccine to DCs on the immunogenicity of aBMC Immunology 2009, 10:43 http://www.biomedcentral.com/1471-2172/10/43
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DNA prime viral vector boost regimen, C57/Bl6 mice
were primed by subcutaneous immunization with a DNA
vaccine encoding a DEC-205-single chain antibody fused
to ovalbumin (DEC-OVA) and boosted with an adenovi-
ral vector expressing ovalbumin (Ad-Ova). The Ad-Ova
vector was used at a suboptimal dose (data not shown) of
5 × 108 particles corresponding to approximately 2 × 107
transducing units in order to better detect the influence of
the DNA prime. Priming with the DEC205-targeted DNA
vaccine (pDEC-Ova) reduced the percentage of Ova
tetramer-positive CD8+ T-cells after the Ad-Ova boost in
comparison to a non-targeted DNA vaccine (pCon-Ova)
encoding ovalbumin fused to a non-reactive single-chain
antibody (Figure 1A). The functional activity of OVA-spe-
cific CD8+ T cells was also assessed by stimulation with the
SIINFEKL peptide followed by staining for interferon-γ
and the degranulation marker CD107a. Consistent with
the tetramer staining, the percentage of Ova-specific
CD107a- and IFNγ-positive CD8+ T cells was lower after
priming with the DEC205-targeted DNA vaccine (Figure
1B). The CD8+ T cell response in mice primed with the
DEC205-targeted DNA Ova vaccine was even lower than
in mice that received the Ad-Ova vaccine in the absence of
a DNA Ova prime, indicating that DEC-205 targeting dur-
ing DNA priming suppressed CD8+  T cell responses
induced by the Ad-Ova vector. This suppressive effect was
dependent on the dose of the DEC205-targeted DNA vac-
cine (Figure 1C) and was also observed for the subpopu-
lation of CD8+ T cells co-expressing IFN-γ and
interleukin-2 (Figure 1D). Reduction of this subpopula-
tion is particularly problematic, since secretion of IL-2 can
promote the expansion of T cells and has been shown to
enhance CD8+ T-cell memory function [22].
Since co-stimulation changes the outcome of DEC205-tar-
geted protein immunizations from peripheral tolerance to
immunity, the DEC205-targeted DNA vaccines were co-
injected with expression plasmids for trimeric soluble
CD40L, a dimeric form of this trimer, or a tetrameric form
of the trimeric CD40L [19]. Although there might be a
trend to enhancement of the priming efficacy of the
DEC205-targeted DNA vaccine by co-expression of the
tetrameric CD40L, this did not reach statistical signifi-
cance (Figure 2A, B). We therefore also explored the effect
of two toll-like receptor (TLR) ligands: CpG-C and Poly
I:C. CpG-C binds to TLR 9 leading to signalling via the
myeloid differentiation primary-response protein 88
(MyD88), while Poly I:C triggers TLR 3 resulting in the
activation of TRIF (TIR domain-containing adaptor pro-
tein inducing interferon-β) (reviewed in [23]). In addi-
tion, Poly I:C also activates the melanoma differentiation-
associated gene-5 (MDA-5) pattern recognition receptor
[24], that is also expressed by many cell types and
involved in anti-viral immune responses (reviewed in
[25]).
Addition of CpG or Poly I:C during priming with the
DEC205-targeted DNA led to a small but significant
enhancement of CD8+ T cell responses after the Ad-Ova
boost. However, a much stronger stimulation of the CD8+
T cell responses was observed with the combination of
CpG and Poly I:C, designated CpI:C. Importantly, the
DEC205-targeted DNA vaccine in the presence of CpI:C
primed significantly stronger CD8+ T cell responses than
the adjuvanted non-targeted DNA vaccine (Figure 2C, D).
This could be confirmed for a wide dose range of the DEC-
205-targeted DNA vaccine (Figure 2E). Priming with 2 μg
of the DEC205-targeted DNA vaccine primed for the viral
vector boost as efficiently as 50 μg of non-targeted DNA
vaccine. Co-stimulation with different combinations of
the TLR ligands and the CD40L did not improve CD8+ T
cell responses of the DNA prime adenoviral vector boost
immunization above the levels obtained by co-stimula-
tion with CpI:C (Figure 2F).
To determine whether the improvement of CD8+ T cell
responses as determined by in vitro assays would be of
functional relevance in vivo, mice were primed with the
DEC-205-targeted DNA vaccine or the non-targeted DNA
vaccine in the presence of CpI:C and boosted with Ad-
Ova. Subsequently, immunized mice were co-injected
with differentially CFSE-labelled syngeneic spleen cells
either loaded with an immunodominant Ova peptide or
not loaded with exogenous peptide. One day after injec-
tion, the percentage of Ova-peptide-loaded cells among
the transferred cells declined to hardly detectable levels in
mice primed with the DEC205-targeted DNA vaccine in
the presence of CpI:C (Figure 3A). The in vivo cytotoxic
activity for Ova-peptide loaded cells was significantly
lower in mice immunized with the non-targeted DNA
prime Ad-Ova boost. As expected, the percentage of Ova-
peptide loaded cells was inversely correlated to the Ova
tetramer positive CD8+ T cells (Figure 3B) measured in
parallel for the same mice.
The HIVp41 Gag antigen was used as an independent anti-
gen to confirm the key findings we had obtained with the
ovalbumin model antigen. Since the immunodominant
Gag epitope, AMQMLKETI, is H2-Kb restricted, Balb/C
mice were primed with a DNA vaccine encoding DEC205-
targeted HIVp41 Gag in the presence or absence of CpI:C
prior to a boost with an adenoviral vector encoding HIV
GagPol (Ad-Hgpsyn). Addition of CpI:C during priming
with the DEC205-targeted HIV-p41 Gag DNA enhanced
Gag-specific IFN-γ producing CD8+ T cells approximately
3-fold (Figure 4A). T-cells producing multiple cytokines
appear to be particularly indicative of protective immu-
nity (reviewed in [26]). We therefore also analysed the
influence of CpI:C on the capacity of CD8+ T cells to
simultaneously produce IFN-γ and IL2. Adding CpI:C dur-
ing priming with the DEC205-targeted HIV-p41 Gag DNABMC Immunology 2009, 10:43 http://www.biomedcentral.com/1471-2172/10/43
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enhanced the percentage of CD8+ T cells double positive
for IFN-γ and IL2 approximately 4-fold (Figure 4B). The
CD8+ T cell response in mice primed with the DEC205-
targeted HIVp41 DNA in the presence of CpI:C was also
higher than in mice primed with adjuvanted non-targeted
DNA vaccines confirming the results obtained with the
ovalbumin model antigen. However, the suppression of
CD8+ T cell responses by targeting the encoded ovalbumin
to DEC205 in the absence of adjuvant could not be
observed for the DEC205-targeted HIVp41 DNA vaccine.
CD8+ T cell responses after priming with a DNA vaccine encoding DEC-205 targeted ovalbumin and boosting with an adenovi- ral vector Figure 1
CD8+ T cell responses after priming with a DNA vaccine encoding DEC-205 targeted ovalbumin and boosting 
with an adenoviral vector. Mice were immunized with the indicated plasmids prior to boosting with adenoviral vectors 
encoding ovalbumin (Ad-Ova) or GFP (Ad-GFP). Unless stated otherwise, a DNA dose of 50 μg was used. One week after the 
boost, the percentage of SIINFEKL/H-2Kb tetramer positive cells (A), IFN-γ and CD107a (B, C) or IFN-γ and IL-2 (D) double-
positive cells after stimulation with the SIINFEKL peptide were determined. A, B) Mean percentages with SEM of three inde-
pendent experiments with a total of eight mice/group are shown. Significant differences (Bonferroni Multiple Comparison test) 
between groups primed with different DNA vaccines and boosted with Ad-OVA are marked (* p < 0.05; ** p < 0.01; *** p < 
0.001). C, D) Dose response curve for DEC-Ova priming. The percentage of IFN-γ and CD107a positive (C) and IFN-γ and IL-
2 positive (D) cells of CD8+ lymphocytes is shown for individual mice.
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CD8+ T-cell responses after priming with DEC-205 targeted DNA vaccines in the presence of costimulatory adjuvants and  boosting with an adenoviral vector Figure 2
CD8+ T-cell responses after priming with DEC-205 targeted DNA vaccines in the presence of costimulatory 
adjuvants and boosting with an adenoviral vector. Mice were primed with DEC-Ova or Con-Ova in the presence or 
absence of the indicated adjuvants (Adj.) prior to boosting with adenoviral vectors encoding ovalbumin (Ad-Ova) or GFP (Ad-
GFP). The percentage of SIINFEKL/H-2Kb tetramer positive cells (A, C, E, F) and IFN-γ and CD107a double-positive cells after 
stimulation with the SIINFEKL peptide (B, D) were determined after the boost. Unless stated otherwise, DEC-Ova and Con-
Ova were used at a dose of 50 μg. A, B, F) Fifty μg of plasmids encoding a soluble trimer (CD40L1), a dimeric form (CD40L2) 
or a tetrameric form of that trimer (CD40L4) were co-administered with the DNA vaccine. C, D, F) CpG, Poly I:C or the com-
bination of CpG and Poly I:C (CpI:C) were coinjected with the plasmids as indicated. E) CpI:C was added during DNA priming. 
Mean percentages with SEM of two independent experiments with a total of eight mice/group are shown (A-D). Mean percent-
ages and SEM of one experiment with four (E) and six (F) mice per group are shown. For reason of clarity, the level of signifi-
cance in the Bonferroni Multiple Comparison test is only indicated for selected group to group comparisons (* p < 0.05; ** p < 
0.01; ***p < 0.001).
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The CD8+ T cell responses were further analysed by in vivo
CTL assays. Priming with the DEC205-targeted HIVp41
DNA in the absence of CpI:C did not enhance in vivo cell
killing after the adenoviral vector immunization, while a
priming effect of the non-targeted DNA vaccine could be
observed (Fig 5). Adding CpI:C to the non-targeted DNA
vaccine slightly enhanced in vivo cell killing, but this dif-
ference did not reach statistical significance. The strongest
in vivo CTL activity was obtained by addition of CpI:C dur-
ing DEC205-targeted HIVp41 DNA priming confirming
the results of the in vivo CTL assays with the Ova model
antigen.
Discussion
Adjuvanting DEC205-targeted DNA vaccines with TLR-
ligands substantially enhanced CD8+ T-cell responses of
the DNA prime viral vector boost regimen. The DEC205-
targeted DNA prime in the presence of CpG and Poly I:C
adjuvants followed by an adenoviral vector boost induced
stronger CD8+ T cell responses than non-targeted DNA
prime adenoviral vector boost immunizations. Since the
latter regimen is considered to be one of the most efficient
ways to induce cytotoxic T cell responses in rodents, non-
human primates and humans this could be an important
achievement. Although pre-existing immunity of human
adenoviral vectors could reduce the immune responses
induced, several strategies to overcome this limitation,
such as the use of rare adenoviral serotypes (reviewed in
[27]) and non-human adenoviruses [28], are presently
persued.
The DEC205-targeted DNA prime adenoviral boost regi-
men also seems to induce substantially stronger CD8+ T
cell responses in comparison to previous DEC205-tar-
geted protein vaccines and DEC205-targeted DNA immu-
nization experiments [8,11]. In these previous
experiments with DEC205-targeted protein vaccines co-
stimulation with anti-CD40 antibody induced optimal
CD8+ and CD4+ T-cell responses [8,10]. We therefore also
explored whether co-expression of different forms of
CD40L could increase the priming efficacy of DEC205-
targeted DNA vaccines. These CD40L expression plasmids
enhance the immunogenicity of DNA vaccines after
repeated intramuscular co-delivery with the DNA vaccine
[19]. We also observed a trend towards enhancement of
CD8+ T-cell responses by co-expression of CD40L during
DNA priming via a single subcutaneous DNA immuniza-
tion. However, due to a larger variation in immune
responses using the subcutaneous vaccination route, the
stimulatory effect by co-expression of CD40L did not
reach statistical significance. Our results also indicate that
DEC205-targeting of antigens encoded by DNA vaccines
could be a double-edged sword. In the absence of addi-
tional stimuli, suppression of CD8+ T cell responses was
observed for the ovalbumin model antigen, but not for
HIVp41 Gag. What governs this different outcome is not
In vivo CTL activity after priming with adjuvanted DNA vaccine encoding ovalbumin and adenoviral vector booster immuniza- tion Figure 3
In vivo CTL activity after priming with adjuvanted DNA vaccine encoding ovalbumin and adenoviral vector 
booster immunization. Mice (n = 3) were primed either with DEC-Ova or Con-Ova in the presence of CpI:C and boosted 
with the Ad-Ova vector. One week after the boost, mice received a 1 to 1 mixture of SIINFEKL peptide-loaded and non-
loaded syngenic donor splenocytes also differing in the intensity of the CFSE-labelling. One day after immunization, the per-
centage of SIINFEKL loaded donor cells (A) and tetramer + CD8+ cells (B) was determined. The levels of significance in the 
Bonferroni Multiple Comparison test are indicated (* p < 0.05; ** p < 0.01; ***p < 0.001).
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understood, but could be related to the affinity of the T-
cell receptor for the antigenic peptide/MHC complex or
antigen-mediated modulation of the state of differentia-
tion or activation of the DCs. Similar mechanisms were
proposed to underlay the different forms of peripheral tol-
erance induced by DEC205-targeted peptide vaccines [6].
At a first glance, the suppressive effects we observed in our
non-adjuvanted ovalbumin DNA prime adenoviral boost
regimen also seems to contradict the enhancement of
DNA vaccination efficacy by DEC205-targeted HIVp41
Gag DNA in the absence of co-stimulation [11]. However,
in the latter study, the DEC205-targeted DNA vaccine was
administered by in vivo electroporation. Since in vivo elec-
troporation induces a strong inflammatory response [29],
the delivery mode might have overcome the requirement
for an additional stimulus, which we observed in the
present study after subcutaneous immunization with the
DNA vaccines. The inflammatory response induced by
electroporation might explain why the DEC205-targeted
HIVp41 DNA vaccine enhanced Gag-specific immune
responses in the absence of adjuvant after in vivo electro-
poration, but not after subcutaneous immunization.
The type of immune response induced by DEC205-tar-
geted protein or DNA vaccines critically depends on the
activation and maturation status of the targeted DCs. This
may vary within one individual depending on the site of
vaccine injection and/or local infections and between
individuals due to differences in the overall activation sta-
tus of the immune system. It might therefore be important
to override the endogenous differentiation status of the
DCs at the injection site of DEC205-targeted vaccines. For
DEC205-targeted DNA vaccines, the innate stimulatory
properties of the injected DNA itself does not seem to be
sufficient for all antigens as indicated by the suppressive
effects induced by the DEC205-targeted DNA expressing
ovalbumin. Although the detection of antigen-specific,
IFN-γ and interleukin 2 secreting CD8+ T cells after prim-
ing with DEC205-targeted DNA vaccines in the presence
of co-stimuli is suggestive for induction of memory
immune responses, it will also be important to evaluate
memory immune responses directly, since they are neces-
sary for long-term protective efficacy after vaccination.
Conclusion
The present study demonstrates that antigen specific
CD8+ T cell responses induced by DNA prime adenoviral
vector boost regimens can be consistently enhanced by
priming with DEC205-targeted DNA vaccines in the pres-
ence of TLR 3 and 9 ligands. Simultaneous stimulation of
the TRIF and MyD88 pathways via TLR3 and TLR9 has
been shown previously to lead to DCs with enhanced T
helper type 1 polarizing capacity [30-32]. Thus, combin-
HIV Gag-specific CD8+ T cell responses Figure 4
HIV Gag-specific CD8+ T cell responses. Mice were primed with a DNA vaccine encoding DEC205-targeted HIV p41 Gag 
(DEC-p41) or control plasmids (Con-p41, mock) with or without CpI:C prior to boosting with an adenoviral vectors encoding 
HIV GagPol (Ad-Hgpsyn) or GFP (Ad-GFP). One week after the boost, the percentage of CD8+ cells also positive for IFN-γ and 
CD107a (A) or IFN-γ and IL2 (B) after stimulation with an immunodominant HIV Gag peptide were determined. Mean percent-
ages with SEM of two independent experiments with a total of eight mice/group are shown. For reason of clarity, the level of 
significance in the Bonferroni Multiple Comparison test is only indicated for selected group to group comparisons (* p < 0.05; 
** p < 0.01; ***p < 0.001).
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ing adjuvants acting synergistically on DCs with DC-tar-
geted vaccines seems to be an particularly attractive
strategy for development of prophylactic or therapeutic
vaccines against chronic viral infections such as HIV and
HCV, in which strong cytotoxic T cell responses are con-
sidered to be of benefit.
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